- Announcing the publication of the first guidelines on treatments for Ebola on Friday, the World Health Organization said that it recommends monoclonal antibodies Inmazeb and Ebanga developed by Regeneron ( NASDAQ: REGN ) and Ridgeback Bio for the viral disease, respectively.
- The decision follows the findings of randomized clinical trials designed to evaluate the therapeutics in Ebola, a severe and often fatal illness caused by the Ebola virus.
- The trials were conducted during the disease outbreaks, and the largest trial got underway in the Democratic Republic of the Congo, the WHO said.
- In addition, the WHO recommended against the use of monoclonal antibody ZMapp and antiviral infusion remdesivir for Ebola.
- ZMapp is developed by San Diego-based drugmaker Mapp Biopharmaceutical, Inc.
- Remdesivir, marketed by Gilead ( GILD ) as Veklury for COVID-19, added $5.6B in sales for the company in 2021, indicating ~98% YoY growth.
For further details see:
Regeneron monoclonal antibody gets WHO recommendation for Ebola